Pfizer, Merck KGaA report their latest setback with checkpoint contender Bavencio
Merck KGaA and their partners at Pfizer have another big setback to report for their PD-L1 checkpoint drug Bavencio.
The checkpoint either alone or in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
